On 15 July 2021, the CMA announced that it had imposed fines totalling more than £260 million for competition law breaches in relation to the supply of hydrocortisone tablets in the UK. The CMA has found that Auden McKenzie and Actavis UK (now known as Accord-UK) charged the NHS excessively high prices for hydrocortisone tablets from 2008-2018 and that Auden McKenzie also paid potential competitors AMCo (now Advanz Pharma) and Waymade to stay out of the market.